Dimensional Fund Advisors LP Has $19.67 Million Position in Exactech, Inc. (EXAC)
Dimensional Fund Advisors LP boosted its position in shares of Exactech, Inc. (NASDAQ:EXAC) by 3.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 780,446 shares of the medical equipment provider’s stock after buying an additional 28,696 shares during the period. Dimensional Fund Advisors LP owned 5.45% of Exactech worth $19,668,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Thomson Horstmann & Bryant Inc. purchased a new stake in Exactech during the first quarter worth about $4,857,000. Royce & Associates LP raised its stake in Exactech by 21.1% in the first quarter. Royce & Associates LP now owns 290,889 shares of the medical equipment provider’s stock worth $7,330,000 after buying an additional 50,761 shares in the last quarter. TFS Capital LLC purchased a new stake in Exactech during the first quarter worth about $1,157,000. Rice Hall James & Associates LLC raised its stake in Exactech by 74.1% in the first quarter. Rice Hall James & Associates LLC now owns 99,270 shares of the medical equipment provider’s stock worth $2,502,000 after buying an additional 42,256 shares in the last quarter. Finally, State Street Corp raised its stake in Exactech by 11.3% in the fourth quarter. State Street Corp now owns 245,639 shares of the medical equipment provider’s stock worth $6,707,000 after buying an additional 25,011 shares in the last quarter. Institutional investors own 64.68% of the company’s stock.
Exactech, Inc. (EXAC) traded down 1.58% during mid-day trading on Friday, hitting $28.05. 27,603 shares of the stock were exchanged. Exactech, Inc. has a 52 week low of $22.20 and a 52 week high of $31.90. The company has a 50 day moving average price of $29.63 and a 200 day moving average price of $27.97. The stock has a market cap of $402.46 million, a price-to-earnings ratio of 539.42 and a beta of 1.02.
Exactech (NASDAQ:EXAC) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $67.75 million. Exactech had a return on equity of 7.39% and a net margin of 0.30%. The business’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.31 earnings per share. Analysts expect that Exactech, Inc. will post $1.29 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Dimensional Fund Advisors LP Has $19.67 Million Position in Exactech, Inc. (EXAC)” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://theolympiareport.com/2017/08/12/dimensional-fund-advisors-lp-has-19-67-million-position-in-exactech-inc-exac.html.
A number of analysts have recently issued reports on EXAC shares. Zacks Investment Research upgraded shares of Exactech from a “sell” rating to a “hold” rating in a research note on Tuesday, April 25th. TheStreet upgraded shares of Exactech from a “c+” rating to a “b” rating in a research note on Tuesday, April 25th. BidaskClub lowered shares of Exactech from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, Gabelli reiterated a “buy” rating on shares of Exactech in a research note on Monday, July 31st.
In other news, CFO Joel C. Phillips sold 7,610 shares of the stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $30.71, for a total transaction of $233,703.10. Following the sale, the chief financial officer now owns 99,907 shares in the company, valued at $3,068,143.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William B. Locander sold 988 shares of the stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $30.34, for a total value of $29,975.92. Following the sale, the director now owns 8,555 shares in the company, valued at approximately $259,558.70. The disclosure for this sale can be found here. Insiders have sold 10,358 shares of company stock worth $314,311 in the last 90 days. Company insiders own 28.30% of the company’s stock.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Want to see what other hedge funds are holding EXAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exactech, Inc. (NASDAQ:EXAC).
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.